Clinical study about application site reaction in the oxybutynin transdermal patch

Clinical study about application site reaction in the oxybutynin transdermal patch - Clinical study about application site reaction in the oxybutynin transdermal patch

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000030425

Enrollment

Registered

2017-12-17

Start date

2016-03-08

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Overactive bladder

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Patients diagnosed with overactive bladder 2) Patients who can provide written informed consent to participate in the study

Exclusion criteria

Exclusion criteria: 1)uroschesis 2)closed-angle glaucoma 3)pylorus, duodenum or intestinal tract blockage 4)paralytic ileus 5)gastric or intestinal atony 6)myasthenia gravis 7)history of oxybutynin hydrochloride hypersensitivity were excluded

Design outcomes

Primary

Measure	Time frame
Evaluation of skin barrier function Evaluation of overactive bladder symptom score	—

Secondary

Measure	Time frame
Evaluation of skin barrier function The skin condition of the lower abdomen, femoral area, and lower back of the participants was evaluated before application of heparinoid cream and oxybutynin transdermal patches. Skin hydration and TEWL were evaluated using Corneometer CM825 and Tewameter TM300 core Severity of OAB was determined by OABSS. OABSS was assessed every 2 weeks from the start of oxybutynin transdermal patch treatment (week 2). OABSS decrease of >3 points during treatment period was considered effective treatment in accordance with the evaluation method described by Gotoh et al.	—

Measure

Time frame

Evaluation of skin barrier function The skin condition of the lower abdomen, femoral area, and lower back of the participants was evaluated before application of heparinoid cream and oxybutynin transdermal patches. Skin hydration and TEWL were evaluated using Corneometer CM825 and Tewameter TM300 core Severity of OAB was determined by OABSS. OABSS was assessed every 2 weeks from the start of oxybutynin transdermal patch treatment (week 2). OABSS decrease of >3 points during treatment period was considered effective treatment in accordance with the evaluation method described by Gotoh et al.

—

Countries

Japan

Contacts

Public ContactYoshihito Murakami

Sunai Pharmacy Co., Ltd. Kuwana pharmacy

yoshihitomurakami5515@gmail.com0594-84-7735

Outcome results